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Abstract
The 2009 World Health Organization report on global health risks identifies hypertension, smoking, raised glucose, physical inactivity, obesity and
dyslipidaemia, in that order, as being the top six modifiable global mortality risk factors. Patients with schizophrenia have high levels of all these risk
factors. There are a small number of studies showing that interventions can improve these, but prospective long-term studies are not available to show
their impact on mortality. A number of studies are now supporting the view that patients with schizophrenia may be dying prematurely as they are not
gaining access to or receiving the same medical care as the general population. The literature now suggests that low cardiorespiratory fitness and
muscle strength are among the strongest predictors of all-cause mortality in the general population. Smoking is still one of the largest risk factors for
premature all-cause mortality. The literature supports the thesis that lifestyle intervention programmes addressing exercise, smoking cessation and
compliance with medication are likely to have significant impact on mortality in schizophrenia. It will be important to ensure that all patients with
schizophrenia have advocates to ensure appropriate treatment and avoid prejudice, and to establish fitness standards in schizophrenia.
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Introduction
In 1911 Bleuler described the group of schizophrenias.
He describes the lives of suﬀerers as unbearable because of
their symptoms, including their ‘Suicidal Drive’ (Bleuler,
1950). The introduction of neuroleptic drugs has been asso-
ciated with reduced suicide rates in those taking them
(Tiihonen et al., 2006), and most live out of institutions.
Many are in sexual relationships and are employed, even in
the professions, with great variation in diﬀerent countries
(Marwaha et al., 2007). However, schizophrenia suﬀerers
lose approximately 25 years of life (Kilbourne et al., 2009).
It now behoves the body of mental health professionals to
recognize the factors leading to the excess mortality and
ﬁnd appropriate preventative measures.
It has long been known that patients with schizophrenia
have a higher prevalence of diabetes mellitus than the general
population (Osborn et al., 2008), but more recently evi-
dence has emerged describing changes such as shortened
telomere length, which are also found in the elderly popula-
tion and smokers (Fernandez-Egea et al., 2009; Kirkpatrick
et al., 2008). How many of these features are innate and how
many are due to environmental factors such as smoking is as
yet unclear.
Research in Finland suggests that the early death rate
from suicide, accident, violence and neglect may be largely
preventable (Tiihonen et al., 2006). Those patients taking
neuroleptics after discharge from hospital have a very much
reduced mortality from these factors compared with those
taking no antipsychotic medication. However, at the other
end of life, these patients are dying prematurely from the
same conditions as the general population: vascular disease
including coronary and cerebral infarction, cancers, respira-
tory, metabolic and kidney disease and more rare conditions
(Saha et al., 2007).
The epidemic of premature deaths in the West from heart
disease in the 1950s and 1960s focussed medical attention on
heart disease. Heart disease now accounts for less than 20%
of mortality (Flegal et al., 2007). Commentators are now
calling for the general factors that reduce all-cause mortality
in the general population to be emphasized, including aerobic
ﬁtness, low blood pressure and non-smoking, which are more
important even than weight and cholesterol (Blair, 2009).
It is noteworthy that these are all modiﬁable features of
healthy living. We know that schizophrenia patients who
have signs similar to premature ageing are more vulnerable
to these diseases (Kelly et al., 2000). Without contrary evi-
dence, we must assume that they are equally sensitive to
healthy modiﬁcation of their lifestyle and appropriate
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episode units for schizophrenia, there is a unique opportunity
to set up long-term prospective studies to quantify baseline
factors related to physical status and the impact of improved
lifestyle and assertive management of both psychiatric and
medical morbidity.
This paper will review the schizophrenia literature to
examine to what extent modiﬁable risk factors cause the
excess mortality and can be managed.
Method
A search was carried out in Medline, Embase and PsycINFO
using the terms: schizophrenia and mortality and modiﬁable
(OR reduction OR intervention). The search strategy covered
the period 1987 until January 2010. Papers were included
from the literature search which examined the link between
schizophrenia and mortality and modiﬁable risk factors.
Papers included in this review were limited to systematic
reviews and meta-analyses when available; otherwise high-
quality studies were reported if possible. Papers were excluded
from the literature which included drug abuse and violence.
In addition, the literature was non-systematically reviewed to
examine the importance of mortality risk factors in the gen-
eral population and whether these can be reduced in patients
with schizophrenia. The search was not carried out to the
standards of the Moose checklist, as no contacts with authors
were made, and no attempt was made to identify unpublished
work or search non-English-language journals.
Results
The literature search identiﬁed 974 papers and ﬁndings from
these papers plus hand searches are described under the fol-
lowing headings:
. Excess mortality in schizophrenia
. Modiﬁable mortality risk factors in the general population
. Modiﬁable mortality risk factors in schizophrenia
. Non-modiﬁable mortality risk factors in schizophrenia
. Review of studies in schizophrenia designed to reduce
mortality
. Can one reduce the mortality risk factors in schizophrenia?
Excess mortality in schizophrenia?
Systematic reviews show that patients with schizophrenia are
at higher risk of mortality than the general population but
are dying of the same causes (Leucht et al., 2007; Saha et al.,
2007). Saha et al. reported that the median standardized mor-
tality rate (SMR) for all-cause mortality was 2.58, with sui-
cide having the highest SMR of 12.86, and the SMRs for
cardiovascular and cancer deaths were 1.79 and 1.37, respec-
tively. Saha et al. highlighted a widening mortality gap for
patients with schizophrenia than the general population,
which was possibly related to people with schizophrenia
having not fully beneﬁted from the improvements in health
treatments available to the general population. This view is
supported by the ﬁnding from Saha et al. that over the
three-decade period for this study, case fatality rates in
schizophrenia have remained constant, whereas in the general
population these have in general declined. However, Leucht
et al. report that stigma may also play an important role,
denying patients access to the best medical care (Leucht
et al., 2007). An earlier review of the excess mortality of
mental disorders (Harris and Barraclough, 1998) showed
the SMRs in schizophrenia for all-cause mortality to be
1.57, and cardiovascular and cancer deaths accounted for
the largest number of deaths with SMRs of 1.04 and 1.00,
respectively. Diﬀerences in the SMRs between these two
reviews and others may be related to the diﬀerences in the
timeframe of the studies included. This view is supported by
changing mortality patterns reported in the general popula-
tion for cancer and heart disease over the period 1975 to 2004
(Capewell et al., 1999; Jemal et al., 2008). The widening gap
in cardiovascular deaths reported by Saha et al. may partially
be associated with diﬀerent historic smoking patterns (Saha,
et al., 2007). Table 1 collates SMRs for patients with schizo-
phrenia and smokers in the general population, showing
Table 1. Standardized mortality ratios (SMR) by disease category in schizophrenia studies and in cigarette smokers in the general population
Causes of death
by disease category
SMR (95% CI)
Schizophrenia
(Harris and
Barraclough, 1998)
Systematic Review
SMR (10–90%
Quantile)
Schizophrenia
(Saha et al., 2007)
Systematic review
SMR (95% CI)
Schizophrenia
(Tran et al., 2009)
Prospective Cohort
study n¼3470, 11 yrs
SMR (95% CI)
Schizophrenia
(Brown et al., 2010)
Prospective linkage
study n¼370, 25 yrs
SMR (95% CI)
Male cigarette smokers
in the general population
(Harris and Barraclough, 1998)
Population¼>18,450
Approximately 40 yrs
All-cause mortality 1.57 (1.53–1.60) 2.58 (1.18–5.76) 3.6 (3.3–3.9) males
4.3 (3.7–5.1) females
2.89 (2.47–3.37) 1.97 (1.92–2.02)
Circulatory 1.04 (1.00–108) 1.79 (1.10–3.60) NOT GIVEN 2.58 (1.95–3.34) 1.85 (1.79–1.91)
Neoplasms 1.00 (0.95–1.06) 1.37 (0.71–2.40) 1.5 (1.20–1.90) 1.49 (1.00–2.12) 2.21 (2.10–2.32)
Respiratory 2.30 (2.13–2.48) 3.19 (2.20–9.30) NOT GIVEN 4.99 (3.26–7.31) 2.97 (2.72–3.22)
Digestive 1.86 (1.64–2.09) 2.38 (1.79–17.5) NOT GIVEN 2.89 (1.16–5.96) 2.84 (2.24–3.57)
38 Journal of Psychopharmacology 24(11)similar raised SMRs across all disease categories except for
neoplasms, which are raised further in smokers. These obser-
vations add support to the argument that a high percentage
of the excess mortality in schizophrenia is possibly smoking
related. A signiﬁcant limitation with most of the mortality
reviews, including those of Saha et al. and Harris et al., is
their retrospective nature (Harris and Barraclough, 1998;
Saha et al., 2007).
One of the ﬁrst modern prospective studies measuring
mortality in schizophrenia comes from France (Tran et al.,
2009). This was an 11-year prospective study which showed
an SMR for all-cause deaths to be 3.6 (men) and
4.3 (women). Suicide (4.2%) accounted for the greatest
number of deaths, followed by cancer (2.2%) and then car-
diovascular disease (2.0%). Lung cancer was the main
cancer killing males (SMR 2.2), with breast cancer being
the main cancer killing females (SMR 2.8). The hazard
ratio (HR) for all cancer deaths in smokers was
HR¼2.59, which is similar to the ﬁndings in smokers in
the general population, HR¼2.21 (Table 1). A UK
25-year prospective linkage study shows a similar mortality
pattern, with an all-cause mortality SMR of 2.89, lung
cancer SMR of 2.65, breast cancer SMR of 1.96, cardiovas-
cular disease SMR of 2.25 and suicide with a very high SMR
of 18.18 (Brown et al., 2010). This study also showed higher
SMRs in smokers (SMR 3.79, 95% CI 3.31–4.59) than in
non-smokers (SMR 1.94, 95% CI 1.25–2.86), and that
mortality was twice as high in smokers than in non-smokers
(Relative Risk (RR) 2.16, 95% CI 1.31–3.59). Smoking-
related diseases accounted for 70% of the excess natural-
cause mortality in this schizophrenia population. Some
73% of the schizophrenia cohort in Brown et al.’s study
smoked, whereas only 53% of the cohort in Tran et al.’s
study smoked, and this may partially explain the higher
SMR for lung cancer in the study from Brown et al.
(SMR 2.65 vs. 2.10, respectively). Over the 25-year period
of Brown et al.’s study, smoking in the general population
fell from 39% to 25%, whereas there was no change in the
smoking pattern in the patients with schizophrenia. Brown
et al. argue that the continued high rates of smoking in the
patients with schizophrenia is likely to explain much of the
excess cardiovascular mortality.
There are some diﬀerences in SMRs between the prospec-
tive studies of Brown et al. and Tran et al. which are not
easily understood. For example, these two recent prospective
studies show contrasting ﬁndings regarding cancer in women,
with the Brown study showing an SMR of 1.02, whereas
Tran et al. showed a ﬁgure of 1.9 (Brown et al., 2010;
Tran et al., 2009). This diﬀerence may be a chance ﬁnding,
as the Brown study was roughly ten times smaller than the
Tran study.
There is consistency among most of the epidemiological
mortality ﬁndings, with SMRs being raised for both natural
and unnatural causes in schizophrenia. However, a number of
studies have found that the increased cancer or heart disease
mortality cannot always be explained by increased incidence,
which suggests that the excess deaths are at least partially
associated with poorer patient access to, and poorer quality
of, health care (Kisely et al., 2007, 2008; Laursen et al., 2009;
Lawrence et al., 2000).
Modifiable mortality risk factors in the general
population
Modiﬁable mortality risk factors can be deﬁned as risk factors
for mortality for which the means to reduce them are known.
The World Health Organization (WHO) (2009) report iden-
tiﬁed the chief global risks for mortality as high blood pres-
sure (13% of deaths globally), tobacco (9%), high blood
glucose (6%), physical inactivity (6%), overweight/obesity
(5%) and high cholesterol (5%). Blair published a ranking
of attributable risk factors for mortality (Blair, 2009), which
was diﬀerent to the WHO (2009) report. He ranked physical
inactivity as the leading attributable cause of mortality (16%
and 17% in men and women, respectively), and diabetes, obe-
sity and lipids had lower attributions (<4%). The diﬀerences
in the ranking may relate to the fact that the WHO (2009)
report does not include research published after 2004, includ-
ing the western population studied by Blair’s research team.
The meta-analysis of cardiorespiratory ﬁtness (CRF) studies
(Kodama et al., 2009) demonstrated the importance of CRF,
which was not only related to cardiovascular mortality but
also correlated with all-cause mortality. These six risk factors
are discussed below.
Physical inactivity/physical fitness. The WHO (2009)
report on global mortality risk factors does not deﬁne what
is meant by physical inactivity. Physical ﬁtness has been
deﬁned in terms of CRF in units of metabolic equivalents
(METS); 1MET is the amount of energy expended at rest,
or 3.5mL oxygen per kilogram per minute. Myers et al.
showed that in both healthy subjects and those with cardio-
vascular disease, a low peak exercise capacity achieved was a
stronger predictor of an increased risk of death than estab-
lished risk factors such as hypertension, smoking, and diabe-
tes (Myers et al., 2002). A study of 9777 men who maintained
or improved adequate physical ﬁtness found that they were
less likely to die from all causes and from cardiovascular dis-
ease during follow-up than persistently unﬁt men (Blair et al.,
1995). This study is important as it shows that ﬁtness training
does bring about a reduction in all-cause mortality. A system-
atic review (Fogelholm, 2010) and meta-analyses (Kodama
et al., 2009) conﬁrm the importance of CRF as an important
risk factor for all-cause mortality. The meta-analysis
(Kodama et al., 2009) showed in relation to the dose-response
analyses, a 1 MET higher level of maximum aerobic capacity
was associated with 13% and 15% decrements in risk of all-
cause and coronary heart disease/cardiovascular disease mor-
tality, respectively.
The research linking CRF to insulin resistance further
highlights its clinical relevance and importance (Leite et al.,
2009). Physical ﬁtness is also being deﬁned in terms of muscle
strength, and a large prospective study showed that mortality,
all-cause, cardiovascular and cancer deaths were strongly cor-
related with low muscle strength (Ruiz et al., 2008).
This study supports the view that cancer mortality can be
reduced through ﬁtness, especially through muscle strength.
The WHO (2009) report indicates that physical inactivity is
estimated to cause around 21–25% of breast and colon
cancer burden.
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stroke, heart disease, kidney failure and increase in other dis-
eases, not only in people with hypertension but also in those
with average, or even below-average, blood pressure.
Lewington et al. reported a twofold increase in stroke death
and a twofold increase in ischaemic heart disease and vascular
death for every 20mmHg increase in systolic blood pressure
>115mmHg (Lewington et al., 2002). A major diﬃculty with
hypertension is that it is often silent, so it is important that all
patients are screened.
Smoking. The WHO (2009) report shows that worldwide
smoking causes 12% of male deaths and 6% of female
deaths. The marked decline in heart disease death between
1975 (320 deaths/100,000) and 2004 (140 deaths/100,000) is
largely ascribed to the reduction in smoking (Capewell et al.,
1999; Jemal et al., 2008). The Massachusetts Tobacco Control
Program, over the period 1993 to 2003, was associated with a
29% reduction in smoking prevalence and a 31% decline in
coronary heart disease mortality rates (Kabir et al., 2008).
Smoking bans have also been associated with signiﬁcant
reductions in admission for coronary care, with Khuder
et al. reporting a 47% reduction at 3 years (Khuder et al.,
2007). Smoking is now recognized to be a signiﬁcant risk
factor for type 2 diabetes (Willi et al., 2007). The ﬁnding
that smoking is a greater health inequality than social class
suggests that unless individuals stop smoking, attempts to
improve their health will be very limited (Gruer et al.,
2009). Doll’s study of male doctors followed up for over 50
years shows that smokers have not shared the increased life-
span of their non-smoking colleagues (Doll et al., 2004).
Diabetes mellitus. The WHO (2009) report suggests that
raised blood glucose is the third largest risk factor for prema-
ture mortality, and worldwide is associated with 5.8% of
deaths. Moreover, it causes all diabetes deaths, 22% of
ischaemic heart disease deaths and 16% of stroke deaths.
The incidence of type 2 diabetes is growing rapidly worldwide
and is associated with increasing levels of obesity and physical
inactivity (Tuomilehto et al., 2001). Type 2 diabetes is asso-
ciated with reduced life expectancy of approximately 8 years
in both men and women (Roper et al., 2001). Mozaﬀarian
reported an 82% reduction in incidence of type 2 diabetes
in people who have the full range of healthy lifestyle factors
(Mozaﬀarian et al., 2009). Mortality in men with diabetes
mellitus has been linked to exercise capacity. In normal-
weight men the relative risk of mortality was RR¼6.6,
95% CI (2.8–15.0); RR¼3.2, 95% CI (1.4–7.0); and
RR¼2.2, 95% CI (1.1–4.6) for the ﬁrst, second, and third
quartiles of ﬁtness, respectively, as compared with the fourth
quartile (p for trend 0.0001) (Church et al., 2004).
Obesity. The WHO (2009) report places overweight and
obesity as being the ﬁfth most important risk factor for
premature mortality. Clearly, morbid obesity is a very signif-
icant mortality risk factor; however, there are new data which
are raising questions about the risk balance for the
overweight category. A US study examining 2.3 million
deaths supports the view of increased risk for diabetes and
kidney disease mortality in the overweight and obese catego-
ries compared with ideal weight (Flegal et al., 2007).
Cardiovascular disease mortality was increased in the obese
categories but not in the overweight category, and there was
signiﬁcantly lower all-cause excess mortality in the overweight
category compared with the obese or ideal weight categories
(Flegal et al., 2007). A study of 13,104 middle-aged individ-
uals for 14 years found that weight gain in middle-aged or
elderly individuals, except in very obese persons, was rela-
tively harmless (Myrskyla ¨ and Chang, 2009).
Karelis et al. challenge the simplistic model of health risks
being associated with increased body weight and discuss the
move towards risk being closely associated with body com-
position, with levels of visceral fat being discriminatory
(Karelis et al., 2004). Visceral fat has been found to be an
independent predictor of all-cause mortality (Kuk et al.,
2006). There are now several studies showing that mortality
is more closely linked to levels of ﬁtness than fatness
(Fogelholm, 2010). However, the use of oﬀspring body
mass index (BMI) as a predictor of own BMI, a technique
that avoids problems of reverse causality, suggests that posi-
tive associations of BMI with all-cause and cardiovascular
mortality may be underestimated in conventional observa-
tional studies.
Cholesterol. Raised cholesterol is highlighted by the WHO
(2009) report as being the sixth most important attributable
cause of mortality in the general population. In the general
population, familial hypercholesterolaemia is a well-
established risk factor for premature mortality. This can
aﬄict as many as 1/67 in some populations (Seftel et al.,
1989). Statins largely prevent the very early mortality of
patients with this abnormality of the low-density lipoprotein
(LDL) cholesterol receptor. Equally, statins reduce mortality
when used in secondary prevention of patients who have
already suﬀered cardiovascular events associated with athero-
sclerosis (Vrecer et al., 2003). The role of statins in the man-
agement of diabetes mellitus is well established, although
recent research shows they also increase the incidence of dia-
betes (Sattar et al., 2010). However, primary prevention mea-
sures of cardiovascular disease in the general population with
raised cholesterol are less clear (Vrecer et al., 2003). Further, a
meta-analysis of 11 studies on 65,229 patients followed up for
244,000 person-years did not ﬁnd evidence for the beneﬁt of
statin therapy on all-cause mortality in a high-risk primary
prevention set-up (Ray et al., 2010). In people aged over
70 there seems to be no beneﬁt to lower cholesterol levels
(Krumholz et al., 1994; Nissinen et al., 1989; Schatz et al.,
2001). No study has shown signiﬁcant reduction of all-cause
mortality for older women (Vos and Rose, 2005). High cho-
lesterol in old age is associated with less dementia (Mielke
et al., 2005). Cloﬁbrate was taken oﬀ the market because of
an increase in all-cause mortality including suicide, although
it reduced cholesterol very well indeed (WHO, 1984). Low
cholesterol has also been linked to suicide (Zureik et al.,
1996). Further, a meta-analysis of studies conﬁrmed a small
statistical link between low cholesterol and suicide, but
40 Journal of Psychopharmacology 24(11)cholesterol-lowering studies did not lead to a signiﬁcant
increase in suicide completers (Lester, 2002).
Diet and alcohol. Although we have reviewed the mortality
risk factors separately, there is emerging evidence that one
needs to look at the impact of combinations of risk factors.
For example, four simple health behaviours – not smoking,
physical activity, eating a balanced diet and having a small
amount of alcohol – were associated with a 14-year increased
life expectancy (Khaw et al., 2008). The Monica study
(Tunstall-Pedoe et al., 1997) showed reduced mortality with
both moderate alcohol consumption and high urinary potas-
sium (a measure of fresh food intake). The WHO (2009)
reported that alcohol, tobacco, high blood pressure, high
BMI, high cholesterol, high blood glucose, low fruit and veg-
etable intake, and physical inactivity account for 61% of car-
diovascular deaths.
Modifiable mortality risk factors in schizophrenia
The literature revealed 974 papers when searched using the
terms schizophrenia and mortality. There were only 12 papers
identiﬁed when using the terms schizophrenia and mortality
and modiﬁable (Table 2). Only one paper was found which
speciﬁcally examined the association between heart disease
mortality and modiﬁable risk factors, both clinical and beha-
vioural, in schizophrenia (Kilbourne et al., 2009). This US
study of 22,817 patients with schizophrenia examined the
association between modiﬁable clinical risk factors (diabetes,
heart disease, hypertension, cerebrovascular disease and other
medical co-morbidities) and behavioural risk factors (current
smoker, hazardous drinking, illicit drug use disorder or phys-
ical activity of less than once a week) for cardiac death
(Kilbourne et al, 2009). The HR for dying from heart disease
associated with schizophrenia was 1.37, and including clinical
and behavioural risk factors, this reduced the HR to 1.17.
The leading behavioural risk factors were lack of physical
activity (HR¼1.66) and current smoker (HR¼1.32).
Among the clinical risk factors, hypertension and diabetes
were signiﬁcant risk factors (HR¼1.38 and 1.51) whereas
hyperlipidaemia was protective (HR¼0.88).
There are several studies and reviews which have
examined the associated risk factors for all-cause mortality
or heart-disease mortality in patients with severe mental
illness (SMI) (Hamer et al., 2008; Osborn et al., 2007,
Table 2. Twelve papers identified using the search terms, schizophrenia & mortality & modifiable, and whether these paper are included in review
Reference Title of paper
Paper referenced
in section of the
paper
* titled:
Modifiable mortality risk
factors in schizophrenia
Paper referenced
in other* sections
of the paper
Kilbourne
et al. (2009)
Excess heart-disease-related mortality in a national study of patients with
mental disorders: identifying modifiable risk factors
YES YES
Saravane et al.
(2009)
Drawing up guidelines for the attendance of physical health of patients with
severe mental illness
NO NO
De Hert et al.
(2009a)
Cardiovascular disease and diabetes in people with severe mental illness
position statement from the European Psychiatric Association (EPA),
supported by the European Associationfor the Study of Diabetes (EASD)
and the European Society of Cardiology (ESC)
YES YES
Haupt et al.
(2009)
Prevalence and predictors of lipid and glucose monitoring in commercially
insured patients treated with second-generation antipsychotic agents.
NO NO
De Hert et al.
(2009b)
Metabolic syndrome in people with schizophrenia: a review. NO NO
Newcomer (2009) Comparing the safety and efficacy of atypical antipsychotics in psychiatric
patients with comorbid medical illnesses.
NO NO
Kelly et al. (2007) Reaching for wellness in schizophrenia. NO NO
Bromet et al.
(2005)
Long-term diagnostic stability and outcome in recent first-episode cohort
studies of schizophrenia.
NO NO
Goff et al. (2005) Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. NO NO
Paton et al.
(2004)
Obesity, dyslipidaemias and smoking in an inpatient population treated with
antipsychotic drugs.
NO NO
Davidson (2002) Risk of cardiovascular disease and sudden death in schizophrenia. NO NO
Haupt and
Newcomer (2001)
Hyperglycaemia and antipsychotic medications. NO NO
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in schizophrenia is a little uncertain, as the disease category
SMI includes a range of mental illnesses and in some cases
includes dementia. However, the USA study (Kilbourne et al.,
2009) reported similar ﬁndings for the association of heart
disease mortality across the same clinical and behavioural
risk factors in bipolar disorder, depression and schizophrenia.
Osborn et al. found that patients with SMI, including schizo-
phrenia, were about three times more likely to die from heart
disease (Osborn et al., 2007). The analysis controlled for
smoking and antipsychotic use, but it did not control for
co-morbid medical conditions (diabetes, obesity, etc.), which
may have explained these associations (Osborn et al., 2007).
The Scottish Health Survey of 597 patients with SMI com-
pared with 19,898 people in the general population examined
the risk factors for all-cause and cardiac mortality over an
8.5-year period (Hamer et al., 2008). The principal ﬁndings
were that patients with a history of psychiatric episodes had a
high risk of all-cause mortality (HR¼3.25, 95% CI
2.63–4.02). Further, patients were more likely to be smokers
(odds ratio (OR)¼4.69), have low physical activity levels
(OR¼2.24), come from a low socioeconomic group
(OR¼2.17) and be separated or divorced (OR¼2.02).
Smoking rates were roughly twice as high in the SMI popu-
lation (62.5% vs. 32.5%), which was associated with under-
weight or morbid obesity, and was less likely to be overweight
and obese.
A French 11-year prospective study of 3470 patients with
schizophrenia showed that among smokers there was a
twofold increase in total cancer deaths (Tran et al., 2009).
This study identiﬁed that there were two important predictors
of death from lung cancer: duration of smoking and age >38
years. Further, this study showed for all cancer deaths the HR
for smokers versus non-smokers was signiﬁcantly raised
(HR¼2.59; 95% CI (1.56–4.32)). A US study of 10 years’
observation in 1213 patients with schizophrenia (Kelly
et al., 2009) conﬁrmed that smoking is a major risk factor
for all-cause mortality. The HR for smokers versus non-
smokers (aged 35–54 years) was HR¼2.1. The 5 and
10-year mortality rates for smokers aged 35–54 years were
7.0% and 14.2%, compared with 3.3% and 10.0% for
non-smokers, respectively. Moreover, cardiac causes were
identiﬁed in 43% of deaths in smokers but in only 19% of
deaths in non-smokers. For those aged 35–54 years, the odds
of cardiac-related death were increased by 12-fold in smokers
relative to non-smokers. The ﬁndings from the UK prospec-
tive linkage study in schizophrenia (Brown et al., 2010) also
supported the view that much of the excess cardiovascular
mortality could be explained by smoking. These studies
demonstrate the signiﬁcant impact of smoking on mortality
in schizophrenia, which is consistent with ﬁndings in the
general population. Moreover, the two recent studies
in schizophrenia (Brown et al., 2010; Tran et al., 2009)
show continuing high smoking rates of 73% and 53%,
respectively.
There has been concern about whether some antipsy-
chotics are associated with an excess cardiovascular mortality
which may be associated with their metabolic proﬁles
(Hennekens et al., 2005). However, De Hert reported that
patients with schizophrenia not taking antipsychotics have a
higher risk for mortality and suicide than patients on regular
antipsychotics, which means that one needs to consider any
metabolic risk within this context (De Hert et al., 2009a).
One of the most recent systematic reviews of antipsychotics
and mortality showed inconsistent ﬁndings, although it
supported the case for increased long-term mortality associ-
ated with antipsychotics as a class (Weinmann et al., 2009).
Only four of these studies, out of 12, covered the time period
when most atypicals became widely used, and none showed
increased mortality with atypicals versus typical antipsy-
chotics. There have subsequently been a number of new stud-
ies published which have examined the risk for all-cause and
cardiovascular mortality in schizophrenia. The 11-year
Finnish study (Tiihonen et al., 2009) showed no increased
risk for cardiovascular disease or all-cause mortality with
antipsychotics. Moreover, long-term treatment with antipsy-
chotics was associated with lower mortality compared with no
antipsychotics (HR¼0.81, 95% CI 0.77–0.84). Their ﬁndings
also showed that for both clozapine and olanzapine, the two
antipsychotics associated with greatest weight gain, that there
were no signs of increased risk of death from ischaemic heart
disease after 7–11 years of cumulative exposure to these
agents. This study has been criticized on methodological
grounds (De Hert et al., 2010); however, its strength is its
size and duration. A US retrospective cohort study examined
the comparative cardiovascular disease mortality between
clozapine (n¼1084) and risperidone (n¼602) over a
10-year period 1994–2004 (Kelly et al., 2010). The risk of
CVD mortality in schizophrenia did not diﬀer between cloza-
pine and risperidone in adults. A US study in patients with
schizophrenia (n¼1920) and controls (n¼9600) found an
inverse association between intensity of antipsychotic use
and risk of myocardial infarction, making a deleterious
eﬀect of antipsychotics unlikely (Enger et al., 2004).
However, several studies have shown increased mortality
with typical antipsychotics (Joukamaa et al., 2006; Osborn
et al., 2007; Waddington et al., 1998). A study in patients
with tardive dyskinesia found higher rates of mortality in
older patients, particularly those on conventional antipsy-
chotics (Dean and Thuras, 2009). A Cochrane review of olan-
zapine versus other atypicals in schizophrenia found no
diﬀerential risk of death, although olanzapine was associated
with greater weight gain (Komossa et al., 2010).
A small number of studies have found that patients with
mental illness have increased mortality rates for cancer, which
is not always explained by increased incidence (Lawrence
et al., 2000). A study from Nova Scotia found that for mel-
anoma, prostate, bladder, and colorectal cancers in males,
incidence rate ratios were lower than might be expected
given the mortality and ﬁrst admission rate ratios, which
were no higher than those of the general population (Kisely
et al., 2008). The author proposed several explanations
including delays in detection or ﬁrst diagnosis leading to
more advanced disease, and also access to medical care.
A study from Denmark found similar ﬁndings in SMI
patients presenting with heart disease (Laursen et al., 2009).
Individuals with severe mental disorder were found to have
only negligible excess rates of contact for heart disease, but
the ﬁndings of excess mortality from heart disease and lower
rates of invasive procedures after ﬁrst contact supports the
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quate. Undertreatment may explain part of their excess car-
diac mortality. A systematic review (Mitchell and Lord, 2010)
supports this view of poor quality of care for patients with
schizophrenia and heart disease.
Non-modifiable mortality risk factors in schizophrenia
There is growing recognition that schizophrenia itself has
innate risk factors for premature mortality. A US study
showed that the illness schizophrenia was associated with
an increased risk of cardiac death, independent of clinical
and behavioural risk factors (Kilbourne et al., 2009).
Complete health visitor records from Hertfordshire in the
UK have allowed follow-up of babies in relation to their
weight. Low birth weight in this population was associated
with increased rates of diabetes and other metabolic disorders
(Phillips et al., 1994). In schizophrenia around 10% of
patients have low birth weight, but to date there are no stud-
ies quantifying physical health outcomes in these patients. A
number of studies are now reporting increased levels of
abnormal glucose in drug-naı¨ve ﬁrst-episode patients
(Spelman et al., 2007), although there are some reports of
negative ﬁndings. Platelet abnormalities related to schizo-
phrenia have been identiﬁed which potentially will increase
the risk of stroke and heart disease (Dietrich-Muszalska and
Olas, 2007; Dietrich-Muszalska et al., 2008) The ﬁndings that
telomere length is reduced in schizophrenia may mean it is a
disease of accelerated ageing (Fernandez-Egea et al., 2009).
The ﬁnding of raised pulse pressure supports the view of
increased risk of diabetes and dementia (Fernandez-Egea
et al., 2009).The ﬁndings of increased levels of homocysteine
in young male patients with schizophrenia is likely to be asso-
ciated with increased risk for cardiovascular disease and
cognitive impairment (Levine et al., 2002). Some studies in
ﬁrst-episode schizophrenia suggest that patients have raised
visceral fat levels, putting them at increased risk for diabetes,
hypertension and cardiovascular disease (Thakore et al.,
2002).
Review of studies in schizophrenia designed to
reduce mortality
We were unable to identify any published prospective studies
in schizophrenia which had been designed to impact on mor-
tality outcomes in schizophrenia. We examined over 974
papers in the systematic literature search.
Can one reduce the mortality risk factors in
schizophrenia?
We must assume that patients with schizophrenia are as sen-
sitive to health-improving measures as the general public.
This section of the paper reviews the literature to examine
the evidence that the top six WHO global mortality risk fac-
tors can be reduced in schizophrenia (WHO, 2009). While
there are established targets for BMI, glucose, lipids and
blood pressure in the general population, it will be important
to establish optimum standards in schizophrenia, as it cannot
be just assumed that the values for the general population
automatically apply in schizophrenia. It will also be impor-
tant to establish whether managing these risks aﬀects long-
term outcomes in schizophrenia, either directly or indirectly
through issues of compliance.
Physical fitness and strength. Those individuals who
developed psychosis are more likely to be physically inactive
(OR¼3.3, 95% CI (1.4–7.9)) and to have poor cardiorespi-
ratory ﬁtness (OR¼2.2, 95% CI (0.6–7.8)) compared with
those who did not develop psychosis (Koivukangas et al.,
2010). Muscular strength and CRF have been correlated
with improvements in all-cause and cardiovascular mortality
in the general population (Kodama et al., 2009; Ruiz et al.,
2008). Most modern guidelines on managing the physical
health risks associated with schizophrenia include a recom-
mendation about the importance of physical activity levels
and ﬁtness. However, to date there are few data published
on the assessment of physical ﬁtness or desired levels to
achieve a lower risk for cardiovascular or all-cause mortality
in schizophrenia. The challenge to improve physical activity
levels will be to determine the optimum programmes (Jerome
et al., 2009), and currently there is a minimal evidence base.
A review of the Cochrane Schizophrenia Group Trial register
identiﬁed three randomized controlled trials of physical activ-
ity or exercise in schizophrenia (Gorczynski and Faulkner,
2010). Its conclusions were that current studies in schizophre-
nia were small, and that regular exercise programmes are pos-
sible, but larger randomized studies are required before any
deﬁnitive conclusions can be drawn.
Assessment of physical activity in schizophrenia has been
described (Lindamer et al., 2008) using the Yale Physical
Activity Scale, stage of motivational readiness scale and an
accelerometer. Using these tools, it was found that persons
with schizophrenia spent less than half their time in physical
activity and expended less than half the kilocalories than the
controls. The Euroﬁt protocol for adults assesses four dimen-
sions of ﬁtness: aerobic ﬁtness, muscular skeletal ﬁtness,
motor ﬁtness and body composition (Oja and Tuxworth,
1995). This assessment tool looks promising, but to date
there is little literature in schizophrenia. A study in Florida
(Beebe et al., 2005) found in 10 patients with schizophrenia
that a 16-week exercise programme which included a 6-min
walking distance was associated with reductions in body fat
(p¼0.03), greater aerobic ﬁtness and lower BMI. A pilot
study in Australia in six patients with schizophrenia
showed, at 3 months, increased ﬁtness level, exercise toler-
ance, reduced blood pressure and upper body and hand
grip strength (Fogarty et al., 2004). Of 31 subjects, 20 com-
pleted a 12-month weight reduction programme which
include an exercise component (Menza et al., 2004). The
results of this simple study were impressive, showing improve-
ments in weight (p<0.02), BMI (p<0.02), haemoglobin
A(1c) levels (p<0.001), diastolic (p<0.001) and systolic
(p<0.05) blood pressure, exercise level (p<0.003), nutrition
knowledge (p<0.0001), and stage of change (exercise
(p<0.0001) and weight (p<0.008)). Vancampfort et al.
examined systematically the impact of simple physical activity
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(Vancampfort et al., 2009). They identiﬁed 13 studies which
showed that physical activity, with and without diet counsel-
ling, resulted in modest weight loss, reductions in systolic and
diastolic blood pressure and decreases in fasting plasma con-
centrations of glucose and insulin. They concluded by stating
that there is a need to develop optimum interventional strat-
egies for prevention and management of cardiometabolic
risks in schizophrenia.
Hypertension. The prevalence of hypertension in schizo-
phrenia is likely to be large, as demonstrated by two recent
studies (Daumit et al., 2008; Smith et al., 2007) which
reported high levels of untreated hypertension (34% and
50%, respectively). However, a systematic review and meta-
analysis only found weak evidence to support excess hyper-
tension in patients with SMI (Osborn et al., 2008). This raises
an important question as to whether one can extrapolate ﬁnd-
ings from an SMI population to schizophrenia populations.
Most guidelines for hypertension in schizophrenia appear to
be extrapolated from the general population. It will be impor-
tant to conﬁrm whether these standards are appropriate in
schizophrenia and which are the best treatments. Moreover,
some antihypertensive drugs and antipsychotics are associ-
ated with sexual side eﬀects, so it will be important to
assess possible interactions.
Piette et al. report a study in 1686 veterans with schizo-
phrenia and comorbid diabetes and hypertension, which
examined the issue of medication compliance (Piette et al.,
2007). This study showed that the adjusted odds of poor
adherence were signiﬁcantly higher for hypoglycaemic and
antihypertensive medications than for antipsychotic medica-
tion (both adjusted ORs were 1.5, p<0.001).
Smoking. Most studies in schizophrenia show smoking rates
to be considerably higher than in the general population
(Catts et al., 2008; Daumit et al., 2008; Williams and
Foulds, 2007). However, the evidence base that it is easily
modiﬁable in schizophrenia is small (Campion et al., 2008).
Rates of smoking cessation in schizophrenia are roughly half
those of the general population (Williams and Foulds, 2007).
As nicotine can interfere with drug metabolism (cytochrome
P450 and CYP1A2) which aﬀects the metabolism of many
antipsychotics including clozapine and olanzapine as well as
haloperidol, smoking cessation needs to be carried out care-
fully, and likewise caution needs to be exercised regarding
dosing in smokers. The evidence base relating smoking as
an important risk factor for mortality in schizophrenia is
very strong (Brown et al., 2010; Catts et al., 2008; Kelly
et al., 2009; Tran et al., 2009). However, there is now
strong evidence in the general population that avoiding pas-
sive smoking has major health beneﬁts (Khuder et al., 2007).
Hence, it will be important to establish smoke-free zones in
clinical and residential areas for patients with schizophrenia.
Glucose. A UK systematic review and meta-analysis exam-
ined the relative risk of diabetes, dyslipidaemia, hypertension
and metabolic syndrome in people with SMI including schizo-
phrenia (Osborn et al., 2008). This review examined 14,000
papers and the principal ﬁndings were that the data quality
was poor, mainly cross-sectional, and often patients were not
adequately screened. This systematic review highlighted a
major gap in our understanding of the prevalence of risks
in SMI and conﬁrmed high rates of diabetes compared with
a control group (RR¼1.87), but weaker evidence for dysli-
pidaemia and hypertension being in excess. However, two
studies (n¼966 and n¼1125), one randomized controlled
trial and one observational (Daumit et al., 2008; Smith
et al., 2007, respectively) report very high levels of hyperten-
sion (34% and 50%, respectively) in schizophrenia.
A number of the current guidelines on the management of
comorbid diabetes in association with schizophrenia support
the view that it is important to manage psychotic symptoms
to be able to manage the diabetes (Holt and Peveler, 2010).
A retrospective chart review (n¼72) demonstrated that using
aggressive anti-diabetic therapy, glycaemic control was
achieved in a group of patients with schizophrenia and
comorbid diabetes mellitus who were treated with atypical
antipsychotics (Krosnick and Wilson, 2005). This study
showed that pre-existing hepatitis was associated with a wors-
ening of diabetes control. Another important question
regarding diabetes is how its management aﬀects schizophre-
nia outcomes. This question has been addressed by 3-year,
prospective, naturalistic study (n¼594) which showed that
the course of schizophrenia did not diﬀer signiﬁcantly
between participants with and without diabetes (Ascher-
Svanum et al., 2007). A community study in the USA exam-
ined how treatment of diabetes in patients with schizophrenia
(n¼101) compared with that in diabetic patients with no
mental illness (n¼99) (Dixon et al., 2004). This study found
that HbA(1c) levels in the patients with schizophrenia were
signiﬁcantly lower than in patients who did not have SMI.
This study concluded that patients with schizophrenia who
are receiving regular mental heath care may have unrecog-
nized beneﬁts for diabetes management. A systematic review
and meta-analysis found that atypical antipsychotics were
associated with a higher risk of diabetes than typical antipsy-
chotics in schizophrenia (Smith et al., 2008). However, a sys-
tematic review of prospective studies found no diﬀerences in
the risk of developing glucose abnormality (Bushe and
Leonard, 2007). A comprehensive review of the risk factors
and management of diabetes in SMI has been published by
the European Psychiatric Association (De Hert et al., 2009a).
Overweight and obesity. There are many studies now
showing that patients with schizophrenia are able to lose
some of their excess weight through weight reduction pro-
grammes, although the weight-loss ﬁgures are modest and
relatively short term. A review of the Cochrane
Schizophrenia Groups trials register identiﬁed 23 randomized
controlled trials, which showed that both behavioural and
pharmacological trials showed modest weight loss results
(Faulkner et al., 2007). The majority of these studies were
short-term studies and not in ﬁrst-episode patients. A system-
atic review found that metformin (eight randomized con-
trolled trials) showed promising weight loss results, but
44 Journal of Psychopharmacology 24(11)again most of the studies were short term (Bushe et al., 2009).
Further, a UK study reported an 8-year experience of a beha-
vioural treatment programme in 112 patients with SMI of
which 64 completed 1 year, and 35 patients 2 years with a
mean weight loss 7.2kg (Holt et al., 2010). A systematic
review and meta-analysis of 10 non-pharmacological
weight-management programmes in schizophrenia found
that this approach was particular helpful in prevention of
early weight gain associated with antipsychotic usage
(Alvarez-Jime ´ nez et al., 2008). They recommended switching
antipsychotics in case of signiﬁcant weight gain, especially
where a poor response had been seen. We were unable to
ﬁnd studies which showed the impact of intentional weight
loss in schizophrenia either on body composition or on long-
term mortality.
Dyslipidaemia. It is well recognized that some patients with
schizophrenia, even prior to treatment, have abnormal levels
of LDL lipids and triglycerides (Kahn et al., 2008; McEvoy
et al., 2007). In the general population there are now many
studies evaluating the impact of lipid lowering in primary and
secondary prevention of coronary heart disease and stroke;
however, there are some concerns about its value in primary
prevention, especially in vulnerable populations (Vrecer,
et al., 2003). Hence, it is a priority to establish studies to
evaluate the risk-beneﬁts of lipid lowering in schizophrenia.
However, until those studies are complete, physicians should
use the relevant NICE guidelines or those speciﬁcally
designed for patients with schizophrenia (De Hert et al.,
2009a; Holt and Peveler, 2010).
A 3-month study demonstrated that statins prescribed to
patients with schizophrenia and severe dyslipidaemia whilst
taking antipsychotic medication led to a signiﬁcant improve-
ment in lipid proﬁles (Hanssens et al., 2007). Similarly, an
earlier study with rosuvastatin proved eﬀective in managing
dyslipidaemia in patients with schizophrenia on antipsy-
chotics (De Hert et al., 2006). This later study showed
improvement in lipid proﬁles but no beneﬁts in terms of
high-density lipoprotein, waist measurement, BMI or glucose
homeostasis. This study supports the view that statins can be
safely used in the short term to control abnormal lipids levels
in schizophrenia. However, there are no long-term data on its
impact on either relapse or all-cause mortality, and again this
is a priority for research. The preferred initial management is
still very much a lifestyle modiﬁcation approach including
exercise and diet.
Discussion
This paper has utilized a systematic search strategy to identify
the impact of modiﬁable mortality risk factors on all-cause
mortality in schizophrenia, and to identify to what extent
there is a literature which shows prospectively that these
risks can be managed. However, this paper was not planned
as a systematic review, as this topic area is too wide to be
covered in one review paper.
The ﬁndings from this paper are that the six top global risk
factors (modiﬁable risk factors) for premature mortality –
hypertension, raised glucose, physical inactivity, overweight
and obesity, and lipids (WHO, 2009) – have either been
shown in research to be, or should in clinical practice be,
amenable to being lowered in patients with schizophrenia.
Moreover, the levels of these risk factors appear to be signif-
icantly raised in schizophrenia compared with the general
population (De Hert et al., 2009a; Leucht et al., 2007; Saha
et al., 2007). There are now many well-documented guidelines
for physical health and wellbeing in schizophrenia (De Hert
et al., 2009a; Lehman et al., 2004; NICE, 2002a; NICE,
2002b). Adopting these guidelines will be an important aid
to minimizing a broad range of physical health risks, includ-
ing both cardiovascular disease and diabetes. However, there
is a dearth of prospective studies about managing these health
risks, which have been shown to work in schizophrenia, hence
the need to set up appropriate studies is urgently required
(Citrome and Yeomans, 2005).
The WHO report on global health risks (WHO, 2009)
quantiﬁes the percentage of deaths globally attributed to
each of the global mortality risk factors. Although these
risk factors are raised in schizophrenia, there are few data
showing their contribution to total mortality in schizophre-
nia. The WHO (2009) report states that understanding the
role of these risk factors is pivotal to developing a clear and
eﬀective strategy for improving global health, hence it will be
important to understand better the contribution of these fac-
tors to total mortality in schizophrenia. The study by
Kilbourne et al. is one of the ﬁrst studies in schizophrenia
to identify the increased HR for cardiac mortality associated
with both behavioural (illicit drug disorder, low physical
activity, smoking and hazardous drinking) and clinical risk
factors (diabetes, hypertension, heart disease, lipids)
(Kilbourne et al., 2009). Paradoxically, this study showed
that high cholesterol was protective for cardiac death. This
ﬁnding will need to be veriﬁed; however, it raises a suspicion
that one cannot assume that the mortality risk factors operate
equally across schizophrenia and the general population.
A number of studies report on modiﬁable mortality risk
factors in patients with SMI and although these ﬁndings are
of interest, there is some uncertainly as to how they relate to
schizophrenia (Hamer et al., 2008; Osborn et al., 2007; Ray
et al., 2009). The ﬁndings from the Scottish Health Survey
further support the view that low physical activity and smok-
ing are major behavioural risk factors for all-cause mortality
(Hamer et al., 2008). Although there are many reviews on
mortality in schizophrenia, including the most recent by
Saha et al. there is little information reported on the issue
of quantiﬁcation of modiﬁable clinical or behavioural risk
factors which could explain the increased mortality risk in
schizophrenia (Saha et al., 2007). This is an important subject
for further research.
The schizophrenia literature has largely failed to address
the issue of ﬁtness, either CRF or muscle strength. This is
possibly understandable, as an editorial pointed out that
although this was now the largest public health challenge,
its importance has not yet been grasped in primary care
(Blair, 2009). Bearing in mind that CRF and muscle strength
are strong indicators of both cardiovascular and all-cause
mortality, it will be important to set up studies to assess
these factors as well as developing programmes to improve
patients function. However, a systematic review on the
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parameters was encouraging (Vancampfort et al., 2009).
The challenge is to develop optimum physical activity pro-
grammes which can be implemented easily into clinical prac-
tice (Jerome et al., 2009).
There is very strong evidence that smoking in schizophre-
nia is a very important modiﬁable mortality risk factor.
Smoking increases the risk of cardiovascular disease in
patients aged 35–54 with schizophrenia by 12-fold (Kelly
et al., 2009). The French study (Tran et al., 2009) showed
that smoking was associated with a twofold increased risk
for all cancer deaths in schizophrenia. The study of Kelly
et al. showed that older patients with schizophrenia who
smoked had a lower mortality rate than older non-smokers.
The authors thought this to be a chance ﬁnding, as the cohort
size for older patients was small. The French study was in a
relatively young population, and also showed a high cardiac
mortality. These ﬁndings raises the question: are patients with
schizophrenia who are young at increased risk of cardiovas-
cular disease and cancer mortality than older patients? In the
general population, passive smoking is now recognized as a
signiﬁcant health risk and it will be important to introduce
smoking bans in psychiatric units and community facilities.
Clinical trials assessing cardiovascular risk in schizophrenia
have largely ignored the impact of passive smoking, which
makes interpretation of the ﬁndings more complex. The ﬁnd-
ings that the SMRs for coronary heart disease are signiﬁ-
cantly increased in schizophrenia raised concerns about the
widening mortality gap with the general population (Saha
et al., 2007). Brown argues that continued high rates of smok-
ing in patients with schizophrenia against a background of
falling smoking rates in the general population can explain
much of the excess cardiovascular and other mortality in
schizophrenia (Brown et al., 2010; Capewell et al., 1999).
The observation of excess mortality associated with smoking
in schizophrenia has also been shown in relation to lung
cancer deaths (Catts et al., 2008).
With the introduction of atypical antipsychotics, which are
associated with increased metabolic risk factors, there has
been a major focus on the metabolic syndrome, cardiovascu-
lar disease and diabetes, which is very proper. With the rec-
ognition that cardiovascular disease mortality is only partially
the explanation of excess deaths in schizophrenia, a focus
needs to move to all-cause mortality (Table 1). This is exem-
pliﬁed by the debate on managing the risk factor overweight/
obese. Intentional weight loss may reduce cardiovascular dis-
ease mortality (Adams, 2009) through reduction in fat, but
weight loss may also lead to increased mortality through loss
of bone and lean mass (muscle and organ). Our knowledge
about weight change and mortality is still very much lacking
(Adams, 2009). An alternative approach has been suggested
(Ross and Bradshaw, 2009) utilizing lifestyle modiﬁcation
programmes characterized by increased physical activity and
balanced diet which can reduce the risk of obesity and risk of
related conditions with minimal change in weight. The bene-
ﬁts of this approach are reductions in abdominal obesity,
visceral fat and cardiometabolic parameters and improve-
ments in muscle mass and CRF (Ross and Bradshaw,
2009). There are some reports of this approach in schizophre-
nia (Smith et al., 2007), but it has attracted little interest as
judged by the number of publications in the literature.
However, support for this approach comes from the UK
(Khaw et al., 2008). This study showed that in the general
population, four health behaviours were associated with
14 years of additional life.
Schizophrenia, the illness itself, appears to be linked to an
increased risk of cardiovascular mortality, HR¼1.17
(Kilbourne et al., 2009). This ﬁnding may be related to genetic
factors or even to low birth weight, but further research is
required to answer this question. There has been a debate
regarding whether antipsychotics themselves are a signiﬁcant
modiﬁable risk factor for excess mortality in schizophrenia.
This debate appeared to start with the introduction of atyp-
ical antipsychotics, which are associated with a greater risk of
weight gain than typical antipsychotics. The ﬁnding that
weight gain in middle-aged and older patients has only a
very small impact on increased mortality risk (Myrskyla ¨
and Chang, 2009) raises a doubt about the initial thinking.
Further, our understanding about cardiovascular risk and
mortality is being challenged, as it has now been shown
that the Framingham risk assessment tool is poor at predict-
ing cardiovascular mortality even in patients identiﬁed to be
at high risk (Beary and Wildgust, 2009; Jackson et al., 2009).
There are also some large epidemiological studies in the gen-
eral population showing that a higher BMI is associated with
a lower risk of suicide (Gravseth, et al., 2010; Magnusson,
et al., 2006). There is also emerging evidence that stopping
antipsychotics is a signiﬁcant mortality risk factor (Tiihonen
et al., 2006). High switching rates between antipsychotics and
a failure to control for smoking, including passive smoking,
may also be important confounders and may possibly explain
some of the inconsistencies in the literature. These ﬁndings
illustrate the complexity in our understanding of the mortality
risk-balance equation in schizophrenia. However, this review
has identiﬁed several studies showing higher mortality risk
associated with typical antipsychotics but no mortality advan-
tage for typicals over atypicals, except for perphenazine
(Tiihonen et al., 2009). These ﬁndings support the view that
if there is a diﬀerential mortality risk across antipsychotics, it
is likely to be small. Large prospective studies are required to
answer this question.
Stress is another potentially modiﬁable mortality risk
factor in schizophrenia, which operates through raised corti-
sol and the hypothalamic–pituitary–adrenal axis. It may be
linked with excess cardiovascular mortality as well as
increased risk of cancer. This is an important topic which
has now been systematically reviewed (Bradley and Dinan,
2010). Research links chronics stress to accelerated telomere
shortening, which is associated with accelerated ageing (Epel
et al., 2004), and in turn may be associated with earlier onset
of cardiovascular and cancer diseases. Cognitive behavioural
treatment has been shown to be eﬀective in reducing stress,
including reduction of raised cortisol. This topic is another
important area for further research.
The literature on modiﬁable mortality risk factors in
schizophrenia conﬁrms that hypertension, smoking, low
physical activity, raised glucose, obesity and cholesterol all
play a role in the mortality risk equation. However, to date
there are few data on how these risk factors combine, or how
they vary by age, and gender, or interact with non-modiﬁable
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risks relating to social class illustrates the complexities in
understanding how risk factors combine (Gruer et al.,
2009). However, the WHO (2009) report suggests that in
the general population, the net impact of combining attribut-
able mortality risk factors is greater than their summation.
It will be important to tease out how these risk factors inter-
play and their eﬀect size in schizophrenia.
Conclusions
There is a very large evidence base supporting increased mor-
tality in schizophrenia for the majority of diseases which
cause death in the general population. In schizophrenia,
rates of smoking, diabetes, hypertension, obesity and abnor-
mal lipids are all high and are all potentially modiﬁable. A
continued high level of smoking, including passive smoking, is
a major mortality risk factor which may partially explain the
excess cardiovascular mortality in schizophrenia. Low ﬁtness,
namely skeletal muscle mass and CRF are two new important
targets established to minimize risk in the general population.
We must assume schizophrenia suﬀerers will beneﬁt equally
from increased ﬁtness, although there is limited evidence sug-
gesting this conclusion. The positive beneﬁts of lifestyle mod-
iﬁcation, based on ﬁndings in the general population, should
encourage psychiatry to adopt these and monitor outcomes.
Psychiatry in combination with general practice needs to
monitor and manage carefully the usual physical health
risks. The ﬁndings that the incidence for a number of medical
conditions in schizophrenia is not raised, yet the correspond-
ing SMRs are increased, support the view that patients with
schizophrenia may not be accessing the care or are receiving
inferior care. Mental health workers need to be advocates to
challenge any prejudice involved.
Our understanding of the quantitative contributions of
modiﬁable mortality risk factors to total mortality in schizo-
phrenia is incomplete. It is important to set up long-term
prospective studies to investigate the importance of these
risk factors and their management to reduce the years lost
to a population enjoying the improved quality of life brought
by modern psychiatric treatments.
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